Triomics nabs $22M to bring oncology-specific AI to cancer centers

Triomics raised $22 million in Series B funding led by Battery Ventures to grow its AI platform for cancer centers. The company helps oncologists and staff automate data-heavy work such as clinical trial matching, appointment prep, patient summaries, and tumor registry reporting using oncology-specific AI.

The funding reflects growing demand for specialized healthcare AI that can handle complex, longitudinal patient records better than generic tools. In oncology, reducing administrative burden could improve clinician productivity, ease burnout, and give doctors more time for direct patient care.